Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Mesoblast, Ltd.
ClinicalTrials.gov Identifier:
NCT00562497
First received: November 20, 2007
Last updated: April 15, 2014
Last verified: May 2012

November 20, 2007
April 15, 2014
September 2007
August 2009   (final data collection date for primary outcome measure)
Achieved an induction of a complete response, Followed by 28 days of maintenance of a clinically meaningful response that does not did not require an increase in corticosteroid dose , did not require second line therapy and survived 90 days. [ Time Frame: 90 Days ] [ Designated as safety issue: No ]
Proportion of patients who have met all of the following conditions; achieved an induction of a complete response, CR, followed by 28 days of maintenance of a clinically meaningful response that does not require an increase in corticosteroid dose greater [ Time Frame: 90 Days ]
Complete list of historical versions of study NCT00562497 on ClinicalTrials.gov Archive Site
Overall response, Induction of a two grade decrease in GVHD and Maintenance, Induction of a CR lasting ≥14 days, Time to CR, Incidence of CR per organ, Total steroid dose through Day 90, Incidence of Steroid/Infectious complications [ Time Frame: 90 Days ] [ Designated as safety issue: No ]
Overall response rate (CR+PR) Induction of a two grade decrease in GVHD, Maintenance of a two grade decrease in GVHD, Induction of a CR lasting ≥14 days, Time to CR, Incidence of CR per organ, Total steroid dose administered through study Day 90, Inc [ Time Frame: 90 Days ]
Not Provided
Not Provided
 
Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD

This is a Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of Prochymal™ versus placebo in combination with corticosteroids as initial therapy for acute GVHD. Corticosteroids have been the primary therapy for patients with previously untreated acute GVHD and the historical published data define an expected 35% complete response (CR) at Day +28 using this therapy.

Subjects will be treated with a total of 6 infusions of investigational agent during the first 4 weeks of the study. Four infusions will be administered during the first two weeks (twice weekly), then two infusions administered during the next two weeks (once weekly). Subjects assigned to the active treatment group will receive Prochymal™. Subjects assigned to the non active treatment group will receive placebo (excipient, less cells). It is recommended that all subjects receive all six infusions. The discontinuation of investigational agent is allowed for GVHD worsening with subsequent need for salvage therapy. All infusions must be given at least 3 days apart.

Subjects will be evaluated for efficacy and safety until death, withdrawal or 90 study days after randomization, whichever occurs first. Study will be unblinded and data analyzed at Day 90 post 1st infusion (Day 0)following final subject enrollment. Subjects will be followed for safety for 12 months post 1st infusion (Day 0).

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Graft Versus Host Disease
  • Drug: Prochymal
    Subjects will be treated with a total of 6 infusions of investigational agent during the first 4 weeks of the study. Four infusions will be administered during the first two weeks (twice weekly), then two infusions administered during the next two weeks (once weekly). Subjects assigned to the active treatment group will receive Prochymal™ at 2 x 106 hMSC/kg per infusion.
  • Other: Placebo
    Subjects will be treated with a total of 6 infusions of investigational agent during the first 4 weeks of the study. Four infusions will be administered during the first two weeks (twice weekly), then two infusions administered during the next two weeks (once weekly). Subjects assigned to the non active treatment group will receive placebo (excipient, less cells). It is recommended that all subjects receive all six infusions. The discontinuation of investigational agent is allowed for GVHD worsening with subsequent need for salvage therapy. All infusions must be given at least 3 days apart.
  • Placebo Comparator: 2
    Placebo
    Intervention: Other: Placebo
  • Active Comparator: 1
    Subjects assigned to the active treatment group will receive Prochymal™.
    Intervention: Drug: Prochymal
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
184
May 2010
August 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects must be 18 years to 70 years of age, inclusive
  • Subjects must have received an allogeneic hematopoietic stem cell transplant using either bone marrow, peripheral blood stem cells or cord blood or administered a donor leukocyte infusion.
  • Subjects must have newly diagnosed Grades B-D acute GVHD. Biopsy confirmation of GVHD is strongly recommended but not required. Randomization should not be delayed awaiting biopsy or pathology results.
  • Subjects must be randomized and treated with corticosteroid (1-2 mg/kg/d methylprednisolone, or equivalent) and Prochymal™/placebo within 72 hours of onset of acute GVHD.
  • Subjects must have adequate renal function as defined by: Calculated Creatinine Clearance of >30mL/min using the Cockroft-Gault equation
  • Subjects who are women of childbearing potential, must be non-pregnant, not breast-feeding, and use adequate contraception. Male subjects must use adequate contraception
  • Subject must have a minimum Karnofsky Performance Level of at least 30 at the time of study entry
  • Subject (or legal representative where appropriate) must be capable of providing written informed consent.

Exclusion Criteria:

  • Subject has been previously treated with systemic immunosuppressive therapy for acute GVHD
  • Subject has any underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would interfere with the evaluation of the subject including uncontrolled infection, heart failure, pulmonary hypertension, etc.
  • Subjects may not receive any other investigational agents (not approved by the FDA for any indication) concurrently during study participation or within 30 days of randomization.
  • Subject has a known allergy to bovine or porcine products or DMSO
  • Subject has received a transplant for a solid tumor disease.
  • Subject requires more than 2L/min of oxygen to maintain stable SaO2 greater than or equal to 92%
  • Subject requires a renal dopamine dose greater than 1-3 mcg/kg/min to maintain renal blood flow associated with renal failure and improved urinary output.
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Canada
 
NCT00562497
265
Yes
Mesoblast, Ltd.
Mesoblast, Ltd.
Not Provided
Study Director: Rod L Monroy, Ph.D. Osiris Therapeutics, Inc.
Mesoblast, Ltd.
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP